Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum...
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrational trial for ...